Sept 10: Scope of Patentable Subject Matter, Bilski ruling
KEI is hosting a brownbag lunch to discuss the scope of patentable subject matter with reference to the Supreme Court's forthcoming decision on Bilski's appeal.
Search Results for: car t
Bristol-Myers Squibb (BMS): Some Examples of Joint Ventures, Partnerships and Alliances
Tuesday, 28 August 2007
Joint Ventures, Partnerships and Alliances with Big Pharma (recent alliance updates can be found here):
Bristol-Myers Squibb Sanofi Pharmaceuticals Holding Partnership – This partnership sells and markets Plavix®. In 2006, the Bristol-Myers Squibb Sanofi Pharmaceuticals Holding Partnership sold in excess of $3.5 billion of Plavix® in the United States. Continue Reading
Novartis (NVS): Some Examples of Joint Ventures, Partnerships, and Alliances
Wednesday, 29 August 2007
According to the Novartis strategic alliances webpage, the company is engaged in "More than 400 collaborations in over 20 countries, over 120 collaborations with major biotech companies, and over 280 collaborations with academic centers."
Selected Joint Ventures, Partnerships, and Alliances with Big Pharma
Novartis and Bayer Schering AG – PTK/ZK – These two companies initially collaborated in the devel Continue Reading
Roche (RHHBY): Select Joint Ventures, Partnerships, and Alliances
Friday, 07 September 2007
Joint Ventures, Partnerships, and Alliances with Big Pharma on PCR Technology Continue Reading
Schering-Plough (SGP): Select Joint Ventures, Partnerships, and Alliances
Friday, 07 September 2007
Select Joint Ventures, Partnerships, and Alliances with Big Pharma Continue Reading
The Protection of Pharmaceutical Test Data: A Policy Proposal, KEI Research Paper 2006:1
Cite as Judit Rius Sanjuan, James Love and Robert Weissman, Protection of Pharmaceutical Test Data: A Policy Proposal, KEI Research Paper 2006:1.
PROTECTION OF PHARMACEUTICAL TEST DATA: A POLICY
PROPOSAL*1
Judit Rius Sanjuan, James Love and Robert Weissman*2
KEI Research Paper 2006:1
21 November 2006
KEI RN 2007:2 Recent examples of compulsory licensing of patents
KEI Research Note 2007:2 [1]
(A PDF version of this is available here.)
Recent examples of the use of compulsory
licenses on patents[1]
KEI Research Note 2007:2
2008 WBU proposal for a WIPO Treaty for Blind, Visually Impaired and other Reading Disabled Persons
The World Blind Union Proposal
- On July 24-25 2008, the World Blind Union (WBU) and KEI
convened an experts meeting to consider a possible WIPO Treaty for
Improved Access for Blind, Visually Impaired and other Reading
Disabled Persons. Continue Reading
KEI Achievements
$1 a day HIV/AIDS drug regimen
In the early 2000s, KEI’s founder, James Love, advocated to lower the price of HIV/AIDS drugs for patients in developing countries. Love convinced generic manufacturer Cipla to sell the standard 3-drug HIV/AIDS regimen for $1 per day, a breakthrough price that saved — and continues to save — millions of lives. Love’s work culminated in the creation of the Global Fund for HIV/AIDS, TB and Malaria and the President’s Emergency Plan For AIDS Relief (PEPFAR), two of the world’s largest providers of HIV/AIDS treatments.
Collective Management of IPR and Patent Pools
UNITAID patent pool for medicines
Cost Benefit Analysis for UNITAID Patent Pool
UNITAIDwebsite on patent pools
MSF website on patent pools